High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• High-grade B-cell lymphoma, not otherwise specified (HGBL-NOS) is a rare and aggressive hematologic malignancy.
• This entity is characterized by high-grade morphologic features and specific genetic rearrangements, distinct from other lymphoma subtypes.

Purpose of the Study:

• To investigate the clinical characteristics, treatment outcomes, and prognostic factors in a cohort of 160 patients with HGBL-NOS.
• To evaluate the efficacy of different first-line chemotherapy regimens in this patient population.

Main Methods:

• Retrospective analysis of multi-institutional data from 160 patients diagnosed with HGBL-NOS.
• Review of patient demographics, clinical presentation, immunophenotypic and genetic features, treatment regimens, and survival data.
• Statistical analysis including survival curves and multivariable modeling to identify prognostic factors.

Main Results:

• HGBL-NOS tumors exhibited significant heterogeneity in immunophenotype and genetic alterations.
• Most patients presented with advanced-stage disease and high-risk clinical factors.
• No significant differences in complete response, progression-free survival (PFS), or overall survival (OS) were observed between DA-EPOCH-R and R-CHOP regimens.
• Key prognostic factors for PFS and OS included poor performance status, elevated lactate dehydrogenase, and dual-expressor immunophenotype; TP53 alterations were associated with dismal PFS.

Conclusions:

• HGBL-NOS is a heterogeneous disease with an overall unfavorable prognosis despite intensive chemotherapy.
• Current diagnostic criteria and therapeutic strategies require refinement to improve outcomes.
• Further research into novel therapeutic approaches is crucial for patients with HGBL-NOS.